China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Down 99.4% in August

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) was the recipient of a large decline in short interest in the month of August. As of August 14th, there was short interest totaling 26,461 shares, a decline of 99.4% from the July 30th total of 4,613,535 shares. Currently, 5.8% of the company’s shares are sold short. Based on an average daily volume of 2,740,460 shares, the short-interest ratio is currently 0.0 days.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on SXTC shares. Weiss Ratings upgraded shares of China SXT Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday, August 11th. Wall Street Zen raised China SXT Pharmaceuticals to a “sell” rating in a research note on Saturday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, China SXT Pharmaceuticals has a consensus rating of “Sell”.

Hedge Funds Weigh In On China SXT Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. XTX Topco Ltd purchased a new position in shares of China SXT Pharmaceuticals during the 4th quarter valued at $36,000. Virtu Financial LLC lifted its holdings in China SXT Pharmaceuticals by 107.5% during the 3rd quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock worth $46,000 after purchasing an additional 15,013 shares in the last quarter. Finally, Citadel Advisors LLC bought a new position in China SXT Pharmaceuticals in the 3rd quarter worth about $78,000. Hedge funds and other institutional investors own 5.02% of the company’s stock.

China SXT Pharmaceuticals Price Performance

NASDAQ SXTC opened at $3.58 on Wednesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.94 and a quick ratio of 7.76. The business has a fifty day simple moving average of $102.70 and a 200 day simple moving average of $137.58. China SXT Pharmaceuticals has a 12 month low of $3.10 and a 12 month high of $83,758.80.

China SXT Pharmaceuticals (NASDAQ:SXTC) last released its quarterly earnings results on Wednesday, July 1st. The company reported ($5.60) earnings per share for the quarter. The company had revenue of $0.26 million for the quarter.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.